But about 2 in 5 adults used GLP-1 drugs solely to lose weight, the KFF poll found
[110] Others, including Natco Pharma ( Semanat and Semafull ) [111] and Mankind Pharma [112] also planned product launches around the same time, and in total, 4050 total brands of semaglutide were expected to become available in India in the following months
This is not unique to retatrutide but is relevant given the aggressive weight loss it produces
At JosephCareRX, patient safety is always our top priority
However, GLP-1RAs should be considered as the preferential add-on therapy in T2DM patients with CKD in case of persistent albuminuria and/or uncontrolled metabolic risks (i.e., inadequate glycemic control, hypertension, overweight/obesity)
Jastreboff AM, Kaplan LM, Frias JP, et al